

Design, synthesis, and biological evaluation of chalcone-linked thiazole-imidazopyridine derivatives as anticancer agents

Vellanki Ragma Suma, Reddymasu Sreenivasulu, Mandava Venkata Basaveswara Rao, Madala Subramanyam, Mohamed Jawed Ahsan,

Medicinal Chemistry Research

ISSN 1054-2523

Volume 29

Number 9

Med Chem Res (2020) 29:1643-1654

DOI 10.1007/s00044-020-02590-9

Your article is protected by copyright and all rights are held exclusively by Springer Science+Business Media, LLC, part of Springer Nature. This e-offprint is for personal use only and shall not be self-archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com".



Design, synthesis, and biological evaluation of chalcone-linked thiazole-imidazopyridine derivatives as anticancer agents

Vellanki Ragha Suma^{1,2} · Reddymasu Sreenivasulu³ · Mandava Venkata Basaveswara Rao⁴ · Madala Subramanyam⁵ · Mohamed Jawed Ahsan⁶ · Ramesh Alluri⁷ · Kuppli Ram Mohan Rao¹

Received: 23 November 2019 / Accepted: 11 June 2020 / Published online: 23 June 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Abstract

A novel library of chalcone linked thiazole-imidazopyridine (**12a–j**) derivatives were designed, synthesized, and their structures were characterized by ¹H NMR, ¹³C NMR and mass spectral studies. Further, all compounds were tested for their anticancer effects on four human cancer cell lines including MCF-7 (breast carcinoma), A549 (lung carcinoma), DU-145 (prostate carcinoma) and MDA MB-231 (breast carcinoma) by employing MTT method, using etoposide as the positive control. Among them, compound **12b** displayed more potent anticancer activity against four cancer cell lines when compared to the positive control.

Keywords Imidazo[4,5-b]pyridine · Zolpidine · Licochalcone A · Chalcone and anticancer activity

Introduction

Now days, cancer is the second leading cause of death after heart disease in developed and undeveloped countries (John and Ross 2010), which is initiated by external (Park et al.

2010; Meffert et al. 2003; Clemens 1991) and internal factors (Mantovani et al. 2008; Clayton et al. 2011; Porta et al. 2011). Cancer treatment has become an important and challenging therapeutic task in medicinal chemistry. The three main treatment strategies employed are surgery, radiation therapy, and chemotherapy. Of these, chemotherapy is one of the important therapy used for the treatment of cancer, which employs chemotherapeutic agents. However, this is associated with various side effects. Hence, the discovery of potent anticancer agents without side effects is a challenge in development of cancer chemotherapeutics for the future generations.

Nitrogen-containing heterocyclic molecules has always attracted significant interest in pharmaceutical industry because of their biological applications. Nitrogen containing imidazo[4,5-b]pyridines are versatile nitrogenized fused hetero-aromatic units that have exhibited potent anticancer properties against a panel of cell lines (Agarwal et al. 2016; Ahsan et al. 2015; Durgesh et al. 2018a, 2018b, 2018c; Hatti et al. 2015a, 2015b; Madhavi et al. 2017b; Murthy et al. 2019; Pragathi et al. 2019; Rao et al. 2019; Reddy et al. 2016a, 2016b; Reddy et al. 2019; Shahinshavali et al. 2019; Spandana et al. 2018a, 2018b; Sreenivasulu et al. 2017; 2018; 2019; 2020; Subramanyam et al. 2018; Suma et al. 2019; Yakantham et al. 2019). It is a structural analog of a purine base. Its derivatives easily interact with the proteins of DNA and RNA. They also show a variety of biological properties like antimetabolic (Temple 1990),

Supplementary information The online version of this article (<https://doi.org/10.1007/s00044-020-02590-9>) contains supplementary material, which is available to authorized users.

✉ Kuppli Ram Mohan Rao
rammohanrao.k@gmail.com

- Department of Chemistry, , GITAM Institute of Science Gandhi Institute of Technology and Management (Deemed to be University), Visakhapatnam, Andhra Pradesh 530045, India
- Department of Chemistry, Government Degree and PG College, Bhadrachalam, Telangana 507111, India
- Department of Chemistry, University College of Engineering (Autonomous), Jawaharlal Nehru Technological University, Kakinada, Andhra Pradesh 533003, India
- Department of Chemistry, Krishna University, Machilipatnam, Andhra Pradesh 521001, India
- Department of Chemistry, SR and BGNR Govt. Arts and Science College (Autonomous), Khammam, Telangana 507002, India
- Department of Pharmaceutical Chemistry, Maharishi Arvind College of Pharmacy, Ambabari Circle, Jaipur, Rajasthan, India
- Vishnu Institute of Pharmaceutical Education & Research (VIPER), Narsapur, Medak, Telangana 502313, India




Fig. 1 Structure of Zolpidem (**1**) and Licochalcone A (**2**)

anticancer (Byth et al. 2006; Kamal et al. 2015, 2010), antifungal (Rival et al. 1991), antiviral (Gudmundsson et al. 2003; Gueiffier et al. 1998), anti-inflammatory (Lacerda et al. 2009), antimicrobial (Al-Tel et al. 2011), antiulcer (Starrett et al. 1989), anti tuberculosic (Bukowski and Kaliszan 1991) and hypnotic (Kercher et al. 2007). Among these, the drug candidate, Zolpidine (**1**, Fig. 1) contains imidazo[4,5-b]pyridine core as a backbone of the structure and is used for the treatment of anxiety (antianxiolytic) (Harrison and Keating 2005; Lancel and Steiger 1999; Langer et al. 1990).

On the other hand, chalcones are the unique class of α , β -unsaturated ketones and are precursors of flavonoids and isoflavonoids (Rozmer and Perjési 2016). The unsaturated ($-\text{COCH}=\text{CH}-$) system is responsible for biological activity exhibited by this class of compounds. These derivatives possess a broad spectrum of biological activities including antimitotic (Ducki et al. 1998), anticancer (Modzelewska et al. 2006), antimalarial (Larsen et al. 2005), antifungal (Lahtchev et al. 2008), antioxidant (Nowakowska 2007), antituberculosis (Lin et al. 2002), antioncogenic (Go et al. 2005), antileishmanial (Nielsen et al. 1998), anti-inflammatory (Rojas et al. 2003), antiviral (Cheenpracha et al. 2006), antibacterial (Liaras et al. 2011) activities and exhibit hyper glycaemic (Satyanarayana et al. 2004) cardiovascular (Furman et al. 2001) properties, induce apoptosis, are cytotoxic (Dimmock et al. 1998). Chalcone functionality is also present in anticancer agents like Licochalcone A (**2**) (2012), which is first isolated from the root of *Glycyrrhiza glabra* (Yoon et al. 2007; Fu et al. 2004). It acts as a human DNA topoisomerase-I inhibitor.

Based on the above information and our continuous efforts, we have synthesized a new series of structurally modified chalcone incorporated thiazole-imidazopyridine (**12a–j**) derivatives and investigated their anticancer activities against a panel of four human cancer cell lines.

Results and discussion

Chemistry

The synthetic route for these compounds **12a–j** is outlined in Scheme 1. Compound pyridin-2-amine (**3**) undergoes

cyclization reaction with 4-methyl cinnamaldehyde (**4**) in the presence of CuBr in ethanol solvent at 60 °C for 8 h to afford 2-p-tolylH-imidazo[1,2-a]pyridine-3-carbaldehyde (**5**). This was then reacted with hydroxyl amine hydrochloride in DMSO solvent and reaction mixture was stirred at 90 °C for 2 h to afford pure 2-p-tolylH-imidazo[1,2-a]pyridine-3-carbonitrile (**6**). This intermediate **6** was converted into thioamide group by reacting with NaSH, $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$ in dry DMF and was stirred at 40 °C for 90 min to provide pure 2-p-tolylH-imidazo[1,2-a]pyridine-3-carbothioamide (**7**). Compound **7** undergoes cyclization with 2-bromo-1-(3,4,5-trimethoxyphenyl)ethanone (**8**) in absolute ethanol at room temperature for 1 h, then stirred at reflux for 20 min to give 3-(4-(3,4,5-trimethoxyphenyl)thiazol-2-yl)-2-p-tolylH-imidazo[1,2-a]pyridine (**9**). Compound **9** was reacted with selenium dioxide in ethanol and reaction mixture was stirred at reflux for 24 h to afford 4-(3-(4-(3,4,5-trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)benzaldehyde (**10**). Furthermore, aldehyde **9** undergoes to Claisen-schmidt condensation reaction with substituted acetophenones (**11a–j**) in the presence of KOH base in ethanol at room temperature for 12 h to provide pure chalcones **12a–j**.


Biological evaluation

In vitro cytotoxicity

The developed compounds (**12a–j**) were screened for their anticancer activity against four human cancer cell lines viz, MCF-7 (breast carcinoma), A549 (lung carcinoma), DU-145 (prostate carcinoma), and MDA MB-231 (breast carcinoma) by using MTT method, and clinical drug etoposide was used as the positive control. Etoposide is employed in chemotherapy medication for the treatment of different types of cancers. Etoposide has 3,5-dimethoxy-4-hydroxy phenyl active scaffold. In the present research, we synthesized different derivatives by varying the substituents on the phenyl ring. Hence we selected Etoposide as standard drug.

Previously reported chalcone derivatives showed medium-to-less anticancer activities against a panel of cancer cell lines (Madhavi et al. 2016, 2017a). But chalcone linked thiazole-imidazopyridine derivatives exhibited potent anticancer activities against four specified cancer cell lines. It can be explained on the basis of insertion of active scaffold “thiazole-imidazopyridine”. Among the ten screened compounds, five compounds (**12b**, **12c**, **12d**, **12i** and **12j**) have exhibited superior potency in anticancer activity on four cell lines. Structure-activity relationship studies indicated that the compound **12b** with electron-rich (3,4,5-trimethoxy) group on the phenyl ring displayed the

Scheme 1 Synthesis chalcone linked thiazole-imidazopyridine derivatives



highest anticancer activity amongst all the compounds screened, with IC_{50} values MCF-7 = $0.18 \pm 0.094 \mu\text{M}$, A549 = $0.66 \pm 0.071 \mu\text{M}$, DU-145 = $1.03 \pm 0.45 \mu\text{M}$ and MDA MB-231 = $0.065 \pm 0.0082 \mu\text{M}$. Compound **12c** with 3,5-dimethoxy group exhibited slightly lower activity (MCF-7 = $0.44 \pm 0.018 \mu\text{M}$, A549 = $1.23 \pm 0.37 \mu\text{M}$, DU-145 = $1.12 \pm 0.25 \mu\text{M}$ and MDA MB-231 = $0.95 \pm 0.066 \mu\text{M}$) compared to compound **12b**. Similarly, compound **12d** having only one methoxy substituent (4-methoxy) also showed decreased activity on four cell lines (MCF-7 = $1.98 \pm 0.52 \mu\text{M}$, A549 = $2.10 \pm 1.66 \mu\text{M}$, DU-145 = $2.44 \pm 1.32 \mu\text{M}$ and MDA MB-231 = $1.81 \pm 0.84 \mu\text{M}$) than **12b** and **12c**. Replacement of 4-methoxy substituent with electron-withdrawing substituent's 4-chloro (**12e**), 4-bromo (**12f**), 4-nitro (**12g**) and 3,5-dinitro (**12h**) declined the biological activity further. Interestingly, compound **12i** with 4-cyano group on the phenyl ring has shown considerable anticancer activity (MCF-7 = $2.33 \pm 1.73 \mu\text{M}$,

A549 = $2.17 \pm 1.50 \mu\text{M}$, DU-145 = $1.90 \pm 0.88 \mu\text{M}$ and MDA MB-231 = $2.02 \pm 0.99 \mu\text{M}$) than **12e–h**. Whereas, compound **12j** having weaker electron-rich group has demonstrated improved anticancer activity on three cell lines like MCF-7 = $1.73 \pm 0.11 \mu\text{M}$, A549 = $1.69 \pm 0.32 \mu\text{M}$, DU-145 = $1.33 \pm 0.45 \mu\text{M}$. compound **12a** which has no substituent, exhibited lesser activity.

From the SAR studies, it could be concluded that the presence of three electron donating $-\text{OCH}_3$ group at 3,4,5 positions on phenyl ring displayed excellent potent anticancer activities against four specified cancer cell lines. Decrease the number of electron donating $-\text{OCH}_3$ groups on phenyl ring would decrease the activity against all specified cancer cell lines. The presence of strong withdrawing group $-\text{NO}_2$ at 3, 5 positions on phenyl ring displayed very less anticancer activity against specified cancer cell lines. Consequently, weak electron-withdrawing groups like bromo and chloro on phenyl ring showed low

Table 1 In vitro cytotoxicity of newly synthesized compounds 12a–j with IC₅₀ in μM^a

Compound	^b MCF-7	^c A549	^d DU-145	^e MDA MB-231
12a	3.29 ± 2.66	4.88 ± 2.87	7.13 ± 3.14	3.86 ± 2.10
12b	0.18 ± 0.094	0.66 ± 0.071	1.03 ± 0.45	0.065 ± 0.0082
12c	0.44 ± 0.018	1.23 ± 0.37	1.12 ± 0.25	0.95 ± 0.066
12d	1.98 ± 0.52	2.10 ± 1.66	2.44 ± 1.32	1.81 ± 0.84
12e	4.25 ± 2.11	ND	5.89 ± 3.23	3.57 ± 2.59
12f	6.36 ± 3.56	10.33 ± 5.48	6.68 ± 3.11	ND
12g	14.85 ± 5.98	16.03 ± 6.19	ND	ND
12h	17.68 ± 6.32	11.55 ± 5.42	9.42 ± 4.62	15.61 ± 5.22
12i	2.33 ± 1.73	2.17 ± 1.50	1.90 ± 0.88	2.02 ± 0.99
12j	1.73 ± 0.11	1.69 ± 0.32	1.33 ± 0.45	3.22 ± 2.48
Etoposide	2.11 ± 0.024	3.08 ± 0.135	1.97 ± 0.45	1.91 ± 0.84

ND not determined

^aEach data is represented as mean ± SD values from three different experiments performed in triplicates.

^bMCF-7: human breast cancer cell line

^cA549: human lung cancer cell line

^dDU-145: human prostate cancer cell line

^eMDA MB-231: human breast cancer cell line

anticancer activities. In this series of derivatives, cytotoxicity effect decreases as the electron donating group is replaced with electron-withdrawing groups Table 1.

Molecular docking studies

The docking studies of all the imidazopyridine analogs (**12a–j**) were carried against three potential targets, protein kinases CLK1 (5X8I), EGFR (2J5F) and tubulin (1SA0) to know the putative mechanism of actions of these new analogs. The docking studies showed the docking scores were found to be comparatively more against the CLK1. The results of molecular docking studies are shown in Table 2. The docking score of compounds **12c** and **12d** were found to be -9.264 and -9.115 respectively showed significant in vitro cytotoxicity. The comparative docking results against the protein kinases, CLK1, EGFR and tubulin are given in Table 1S (Supplementary information). The imidazopyridine analogs were also reported as protein kinases CLK1 inhibitor (Patent WO2017222285A1). The imidazopyridine analogs were well accommodated in the active site of protein kinase CLK1. The binding mode of all the imidazopyridine analogs against the protein kinase CLK1 is shown in Fig. 2. All the analogs bind in a similar ways (Fig. 3a) except compound, **12g**, which is shown in Figs. 2 and 3b with specific saffron color. The carbonyl functions of ligands, **12b**, **12c**, **12f**, and **12i** showed H-bonding with residues Lys191. The carbonyl function of ligand, **12h** showed H-bonding with the residue Lys191 and nitro function showed slat bridges with the residues Asp288, Asp325, and Lys290. The respective carbonyl and methoxy functions of ligands, **12a**, **12e**, and **12j**, showed

Table 2 Molecular docking studies of the title compounds, 12a–j against protein kinase, CLK1

S. No.	Compounds	Molecular docking studies	
		D Score	Emodel
1	12a	-8.795	-105.360
2	12b	-9.264	-115.063
3	12c	-9.115	-111.646
4	12d	-8.548	-109.363
5	12e	-8.885	-106.392
6	12f	-9.017	-107.381
7	12g	-8.619	-111.476
8	12h	-9.705	-122.674
9	12i	-8.955	-108.793
10	12j	-8.794	-105.595

H-bonding with the residue Lys191 and Lys290, respectively. However the carbonyl function of ligand, **12g**, showed H-bonding with the residue Lys290. The methoxy function of ligand, **12d** showed H-bonding with the residue Lys290. The imidazopyridine fragments of analogs, **12a–f** lies in the hydrophobic cavity of protein kinase CLK1 surrounded by the residues, Phe326, Val324, Phe241, Leu243, Leu244. The compounds **12b** and **12c** showed significant in vitro cytotoxicity and their binding mode against the active site of protein kinase CLK1 is shown in Figs. 4 and 5. They showed similar type of binding in the active site of CLK1. The binding modes of imidazopyridine analogs, **12a**, and **12d–f** are shown in Fig. 1S, while the binding modes of imidazopyridine analogs, **12g–j** are shown in Fig. 2S (Supplementary information).




Fig. 2 The binding mode of all the imidazopyridine analogs (**12a-j**) against the active site

Experimental section

All chemicals and reagents were obtained from Aldrich (Sigma-Aldrich, St. Louis, MO, USA), Lancaster (Alfa Aesar, Johnson Matthey Company, Ward Hill, MA, USA) and were used without further purification. Reactions were monitored by TLC, performed on silica gel glass plates containing 60 F-254, and visualization on TLC was achieved by UV light or iodine indicator. ^1H and ^{13}C NMR spectra were recorded on Gemini Varian-VXR-unity (400 MHz, 300 MHz) instrument. Chemical shifts (δ) are reported in ppm downfield from internal TMS standard. ESI spectra were recorded on Micro mass, Quattro LC using ESI+ software with capillary voltage 3.98 kV and ESI mode positive ion trap detector. Melting points were determined with an electro thermal melting point apparatus, and are uncorrected.




Fig. 3 a Binding mode of imidazopyridine analogs **12a-j** except **12g**. b. Binding mode of imidazopyridine analogs **12a-j** including **12g**





Fig. 4 Binding mode of ligand **12b** and **12c** against the active site of protein kinase CLK1

Fig. 5 Binding mode of ligand **12b** and **12c** against the active site of protein kinase CLK1



2-p-TolyIH-imidazo[1,2-a]pyridine-3-carbaldehyde (5)

To the mixture of 2-amino pyridine (**3**) (13 g, 0.138 mmol) and (E)-3-p-tolylacrylaldehyde (**4**) (24.2 g, 0.166 mmol) taken in ethanol, 10 mol% CuBr (1.98 g, 0.0138 mmol) was added and the reaction mixture was stirred at 60 °C for 8 h. After completion of the reaction (monitored by TLC), the reaction mixture was filtered using the Whatman paper. The filtrate was dried on rotavapor and was then extracted with water and ethyl acetate. Ethyl acetate layer was dried over anhydrous sodium sulfate and evaporated on vacuum rotavapor to give crude product. The crude product was purified by column chromatography using n-hexane and ethyl acetate to provide pure colorless product **5** as yellow color solid, in 23.8 g with 61% yield. mp: 168–169 °C; ¹H NMR (300 MHz, CDCl₃): δ 2.47 (s, 3H), 7.08 (d, 2H, *J* = 8.1 Hz), 7.13 (t, 1H), 7.56 (t, 1H), 7.81 (d, 2H, *J* = 8.1 Hz), 7.85 (d, 1H, *J* = 8.0 Hz), 9.68 (d, 1H, *J* = 8.0 Hz), 10.12 (s, 1H); ¹³C NMR (75 MHz, CDCl₃): δ 21.7, 115.3, 117.8, 120.3, 128.8, 129.5, 130.1, 130.8, 141.0, 147.9, 158.9, 179.6; MS (ESI): *m/z* 237 [M + H]⁺; Anal. Calcd for C₁₅H₁₂N₂O: C, 76.25; H, 5.12; N, 11.86. Found: C, 76.03; H, 4.99; N, 11.71.

2-p-TolyIH-imidazo[1,2-a]pyridine-3-carbonitrile (6)

A mixture of 2-p-tolyIH-imidazo [1,2-a]pyridine-3-carbaldehyde (**5**) (23 g, 0.097 mmol) and NH₂OH·HCl (7.45 g, 0.107 mmol) in DMSO (50 ml) was stirred at 90 °C for 2 h. After completion of the reaction as confirmed by TLC (20% EtOAc in hexane), the mixture was cooled and diluted with H₂O. The solid precipitated was collected by filtration, washed with H₂O and dried under suction to afford pure nitrile compound **6** as half white color solid, in 16.2 g with 71% yield. mp: 160–162 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.47 (s, 3H), 7.10 (d, 2H, *J* = 8.2 Hz), 7.15 (t, 1H), 7.57 (t, 1H), 7.83 (d, 2H, *J* = 8.2 Hz), 7.85 (d, 1H, *J* = 8.0 Hz), 9.68 (d, 1H, *J* = 8.0 Hz); ¹³C NMR (75 MHz, CDCl₃): δ 21.6, 93.3, 113.2, 114.8, 118.6, 125.9, 127.5, 128.2, 129.10129.8, 140.6, 146.9, 153.6; MS (ESI): *m/z* 236 [M + H]⁺; Anal. Calcd for C₁₅H₁₁N₃: C, 77.23; H, 4.75; N, 18.01. Found: C, 77.06; H, 4.63; N, 17.85.

2-p-TolyIH-imidazo[1,2-a]pyridine-3-carbothioamide (7)

To a slurry of 70% sodium hydrosulfide hydrate (7 g, 0.125 mmol) and magnesium chloride hexahydrate (12.97 g, 0.0638 mmol) in 45 ml of DMF, 2-p-tolyIH-imidazo[1,2-a]pyridine-3-carbonitrile (**6**) (15 g, 0.0638 mmol) was added in one portion, and the mixture was stirred at room temperature for 90 min. The resulting green slurry was poured into 100 ml of water, and the precipitates obtained were collected by filtration. The crude product was suspended in 1 N HCl and stirred for 20 min, then filtered and

washed with water to afford pure compound **7** as half white color solid, in 12.9 g with 76% yield. mp: 211–214 °C, ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.47 (s, 3H), 7.11 (d, 2H, *J* = 8.3 Hz), 7.16 (t, 1H), 7.58 (t, 1H), 7.84 (d, 2H, *J* = 8.3 Hz), 7.86 (d, 1H, *J* = 8.1 Hz), 9.33 (s, 2H), 9.66 (d, 1H, *J* = 8.1 Hz); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 21.3, 113.4, 114.6, 116.3, 121.2, 125.6, 130.8, 132.0, 138.9, 140.2, 148.6, 178.3; MS (ESI): *m/z* 268 [M + H]⁺; Anal. Calcd for C₁₅H₁₃N₃S: C, 67.39; H, 4.90; N, 15.72. Found: C, 67.22; H, 4.78; N, 15.55.

3-(4-(3,4,5-Trimethoxyphenyl)thiazol-2-yl)-2-p-tolyIH-imidazo[1,2-a]pyridine (9)

The compounds 2-bromo-1-(3,4,5-trimethoxyphenyl)ethanone (**8**) (13 g, 0.045 mmol) and 2-p-tolyIH-imidazo[1,2-a]pyridine-3-carbothioamide (**7**) (12 g, 0.045 mmol) were dissolved in absolute ethanol and reaction mixture was stirred at room temperature for 1 h and then refluxed for 20 min. After cooling, the precipitate obtained was filtered and neutralized with sodium acetate base, recovered from the HBr salts. The crude product was recrystallized twice from ethanol solvent to afford pure compound **9** as half white color solid, 14.3 g with 70% yield. mp: 201–203 °C; ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.47 (s, 3H), 3.87 (s, 6H), 3.90 (s, 3H), 7.13 (d, 2H, *J* = 8.4 Hz), 7.17 (t, 1H), 7.38 (s, 2H), 7.59 (t, 1H), 7.85 (d, 2H, *J* = 8.5 Hz), 7.88 (d, 1H, *J* = 8.2 Hz), 8.23 (s, 1H), 9.69 (d, 1H, *J* = 8.2 Hz); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 21.6, 56.3, 61.1, 103.6, 108.9, 114.6, 120.1, 127.6, 128.0, 130.1, 131.1, 131.8, 132.5, 135.3, 139.1, 140.6, 145.9, 149.0, 154.1, 159.1; MS (ESI): *m/z* 458 [M + H]⁺; Anal. Calcd for C₂₆H₂₃N₃O₃S: C, 68.25; H, 5.07; N, 9.18. Found: C, 68.42; H, 4.91; N, 9.36.

4-(3-(4-(3,4,5-Trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)benzaldehyde (10)

A mixture of compound (**9**) (13 g, 0.0284 mmol), SeO₂ (15.8 g, 0.142 mmol) and 70 ml ethanol was stirred at reflux for 24 h. After completion of the reaction, the mixture was cooled to room temperature and filtered through a celite pad. The filtrate was evaporated by vacuum and diluted with 50 ml water and extracted with 150 ml of CH₂Cl₂. The CH₂Cl₂ layer was washed with saturated NaHCO₃ solution, dried over anhydrous sodium sulfate. The crude product was purified by column chromatography by using hexane:ethyl acetate (4:6) as eluent to afford pure aldehyde **10**, as half white color solid, in 10.8 g with 81% yield. mp: 224–226 °C. ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.87 (s, 6H), 3.90 (s, 3H), 7.18 (d, 2H, *J* = 8.5 Hz), 7.20 (t, 1H), 7.38 (s, 2H), 7.60 (t, 1H), 7.86 (d, 2H, *J* = 8.5 Hz), 7.89 (d, 1H, *J* = 8.2 Hz), 8.24 (s, 1H), 9.69 (d, 1H, *J* = 8.2 Hz), 10.35 (s, 1H); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 56.1, 60.9, 103.4, 108.6,

109.8, 114.6, 120.1, 126.9, 128.0, 130.3, 131.1, 132.6, 138.1, 138.9, 139.3, 145.7, 148.3, 154.1, 158.9, 191.4; MS (ESI): m/z 472 $[M + H]^+$; Anal. Calcd for $C_{26}H_{21}N_3O_4S$: C, 66.23; H, 4.49; N, 8.91. Found: C, 66.06; H, 4.36; N, 8.78.

(2E)-3-(4-(3-(4-(3,4,5-Trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)-1-phenylprop-2-en-1-one (12a)

A mixture of acetophenone (**11a**) (0.13 ml, 0.001 mmol) and 4-(3-(4-(3,4,5-trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)benzaldehyde (**10**) (500 mg, 0.001 mmol) was dissolved in 20 ml ethanol. To this mixture, potassium hydroxide (40%, 1 ml) was added at 0–5 °C. The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was poured over crushed ice and acidified with dil HCl. The light yellow solid thus obtained was filtered, washed with water and dried. The residue was purified on column chromatography by using ethyl acetate/hexane (7:3) to afford compound **12a** as half white color solid, 212.6 mg with 35% yield. mp: 254–256 °C; 1H NMR (300 MHz, DMSO- d_6): δ 3.87 (s, 6H), 3.90 (s, 3H), 7.10 (d, 1H, $J = 15.6$ Hz), 7.18 (d, 2H, $J = 8.5$ Hz), 7.20 (t, 1H), 7.38 (s, 2H), 7.42 (t, 1H), 7.61 (t, 1H), 7.87–8.00 (m, 4H), 8.24 (s, 1H), 9.69 (d, 1H, $J = 8.2$ Hz); ^{13}C NMR (75 MHz, DMSO- d_6): δ 57.4, 61.5, 104.7, 109.2, 115.6, 120.3, 122.4, 127.6, 127.9, 128.3, 129.7, 131.2, 131.6, 134.5, 135.6, 135.8, 139.6, 146.3, 149.6, 154.2, 159.7, 170.5; MS (ESI): m/z 574 $[M + H]^+$; Anal. Calcd for $C_{34}H_{27}N_3O_4S$: C, 71.19; H, 4.74; N, 7.32. Found: C, 71.06; H, 4.63; N, 7.47.

(2E)-1-(3,4,5-Trimethoxyphenyl)-3-(4-(3-(4-(3,4,5-trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)prop-2-en-1-one (12b)

This compound **12b** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 1-(3,4,5-trimethoxyphenyl)ethanone (**11b**) (210 mg, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 8:2) to afford pure compound **12b** as half white color solid, 233.4 mg with 33% yield. mp: 276–278 °C, 1H NMR (300 MHz, DMSO- d_6): δ 3.79 (s, 6H), 3.87 (s, 6H), 3.90 (s, 3H), 3.94 (s, 3H), 7.09 (d, 1H, $J = 15.7$ Hz), 7.17 (d, 2H, $J = 8.3$ Hz), 7.19 (t, 1H), 7.30 (s, 2H), 7.38 (s, 2H), 7.60 (t, 1H), 7.84–7.95 (m, 4H), 8.24 (s, 1H), 9.69 (d, 1H, $J = 8.2$ Hz); ^{13}C NMR (75 MHz, DMSO- d_6): δ 57.4, 57.8, 61.5, 61.7, 104.5, 107.3, 109.3, 115.6, 120.4, 124.6, 127.5, 127.9, 128.3, 128.7, 131.4, 131.7, 134.6, 134.8, 135.7, 139.5, 140.6, 145.3, 145.9, 146.3, 149.6, 152.4, 154.3, 159.7, 171.3; MS (ESI): m/z 664 $[M + H]^+$; Anal. Calcd for $C_{37}H_{33}N_3O_7S$: C, 66.95; H, 5.01; N, 6.33. Found: C, 66.82; H, 4.88; N, 6.46.

(2E)-1-(3,5-Dimethoxyphenyl)-3-(4-(3-(4-(3,4,5-trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)prop-2-en-1-one (12c)

This compound **12c** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 1-(3,5-dimethoxyphenyl)ethanone (**11c**) (180 mg, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 8:2) to afford pure compound **12c** as half white color solid, 248.7 mg with 37% yield. mp: 267–269 °C, 1H NMR (300 MHz, DMSO- d_6): δ 3.69 (s, 6H), 3.87 (s, 6H), 3.90 (s, 3H), 6.88 (s, 1H), 7.11 (d, 1H, $J = 15.6$ Hz), 7.18 (d, 2H, $J = 8.4$ Hz), 7.19 (t, 1H), 7.34 (s, 2H), 7.38 (s, 2H), 7.60 (t, 1H), 7.88–7.97 (m, 4H), 8.25 (s, 1H), 9.69 (d, 1H, $J = 8.2$ Hz); ^{13}C NMR (75 MHz, DMSO- d_6): δ 56.4, 57.5, 61.5, 104.5, 109.4, 110.5, 112.4, 115.6, 120.6, 124.7, 127.5, 127.9, 128.5, 128.8, 131.5, 131.7, 134.6, 134.8, 135.7, 139.5, 144.5, 145.8, 146.3, 149.6, 154.2, 159.3, 160.5, 171.4; MS (ESI): m/z 634 $[M + H]^+$; Anal. Calcd for $C_{36}H_{31}N_3O_6S$: C, 68.23; H, 4.93; N, 6.63. Found: C, 68.06; H, 4.81; N, 6.49.

(2E)-1-(4-Methoxyphenyl)-3-(4-(3-(4-(3,4,5-trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)prop-2-en-1-one (12d)

This compound **12d** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 1-(4-methoxyphenyl)ethanone (**11d**) (150 mg, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 8:2) to afford pure compound **12d** as half white color solid, 220.6 mg with 34% yield. mp: 260–262 °C, 1H NMR (300 MHz, DMSO- d_6): δ 3.87 (s, 6H), 3.90 (s, 3H), 3.93 (s, 3H), 6.88 (s, 1H), 7.08–7.13 (m, 3H), 7.18 (d, 2H, $J = 8.5$ Hz), 7.20 (t, 1H, c_7), 7.38 (s, 2H), 7.43 (d, 2H, $J = 8.7$ Hz), 7.61 (t, 1H), 7.85–7.98 (m, 4H), 8.25 (s, 1H), 9.12 (d, 2H, $J = 8.7$ Hz), 9.69 (d, 1H, $J = 8.2$ Hz); ^{13}C NMR (75 MHz, DMSO- d_6): δ 56.5, 57.5, 61.6, 104.6, 109.5, 114.5, 115.7, 120.5, 122.4, 127.5, 127.8, 128.4, 128.7, 129.4, 131.5, 131.7, 134.6, 134.8, 135.7, 139.6, 145.4, 146.8, 149.4, 154.6, 159.7, 164.8, 171.7; MS (ESI): m/z 604 $[M + H]^+$; Anal. Calcd for $C_{35}H_{29}N_3O_5S$: C, 69.64; H, 4.84; N, 6.96. Found: C, 69.81; H, 4.72; N, 7.12.

(2E)-1-(4-Chlorophenyl)-3-(4-(3-(4-(3,4,5-trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)prop-2-en-1-one (12e)

This compound **12e** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 1-(4-chlorophenyl)ethanone (**11e**)

(0.13 ml, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 7:3) to afford pure compound **12e** as half white color solid, 342.7 mg with 53% yield. mp: 287–289 °C, ^1H NMR (300 MHz, DMSO- d_6): δ 3.87 (s, 6H), 3.90 (s, 3H), 7.12 (d, 1H, $J = 15.8$ Hz), 7.19 (d, 2H, $J = 8.6$ Hz), 7.21 (t, 1H), 7.38 (s, 2H), 7.51 (d, 2H, $J = 8.8$ Hz), 7.61 (t, 1H), 7.87–8.03 (m, 4H), 8.27 (s, 1H), 9.18 (d, 2H, $J = 8.8$ Hz), 9.69 (d, 1H, $J = 8.2$ Hz); ^{13}C NMR (75 MHz, DMSO- d_6): δ 57.6, 61.7, 104.6, 109.7, 115.6, 120.4, 122.3, 127.6, 127.9, 128.4, 128.7, 130.4, 131.5, 131.8, 132.3, 134.6, 134.8, 135.7, 137.6, 139.5, 140.6, 145.7, 146.3, 149.7, 154.3, 159.6, 172.6; MS (ESI): m/z 608 $[\text{M} + \text{H}]^+$; Anal. Calcd for $\text{C}_{34}\text{H}_{26}\text{ClN}_3\text{O}_4\text{S}$: C, 67.15; H, 4.31; N, 6.91. Found: C, 67.03; H, 4.44; N, 7.07.

(2E)-1-(4-Bromophenyl)-3-(4-(3-(4-(3,4,5-trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)prop-2-en-1-one (12f)

This compound **12f** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 1-(4-bromophenyl) ethanone (**11f**) (199 mg, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 7:3) to afford pure compound **12f** as half white color solid, 289.7 mg with 42% yield. mp: 293–295 °C, ^1H NMR (300 MHz, DMSO- d_6): δ 3.87 (s, 6H), 3.90 (s, 3H), 7.11 (d, 1H, $J = 15.7$ Hz), 7.18 (d, 2H, $J = 8.6$ Hz), 7.20 (t, 1H), 7.38 (s, 2H), 7.56 (d, 2H, $J = 8.7$ Hz), 7.61 (t, 1H), 7.86–7.94 (m, 4H), 8.26 (s, 1H), 9.10 (d, 2H, $J = 8.7$ Hz), 9.69 (d, 1H, $J = 8.2$ Hz); ^{13}C NMR (75 MHz, DMSO- d_6): δ 57.5, 61.6, 104.6, 109.7, 115.6, 120.5, 122.4, 127.5, 127.9, 128.5, 128.7, 129.3, 131.5, 131.7, 132.5, 132.7, 134.5, 134.8, 136.5, 137.2, 139.5, 145.3, 146.5, 149.7, 154.4, 159.7, 171.7; MS (ESI): m/z 654 $[\text{M} + \text{H}]^+$; Anal. Calcd for $\text{C}_{34}\text{H}_{26}\text{BrN}_3\text{O}_4\text{S}$: C, 62.58; H, 4.02; N, 6.44. Found: C, 62.41; H, 4.16; N, 6.59.

(2E)-3-(4-(3-(4-(3,4,5-Trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)-1-(4-nitrophenyl)prop-2-en-1-one (12g)

This compound **12g** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 1-(4-nitrophenyl) ethanone (**11g**) (165 mg, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 7:3) to afford pure compound **10g** as half white color solid, 365.4 mg with 56% yield. mp: 300–302 °C, ^1H NMR (300 MHz, DMSO- d_6): δ 3.87 (s, 6H), 3.90 (s, 3H), 7.15 (d, 1H, $J = 15.7$ Hz), 7.17–7.25 (m, 3H), 7.38 (s, 2H), 7.62 (t, 1H), 7.86–7.94 (m, 4H), 8.15 (d, 2H, $J = 8.9$ Hz), 8.27 (s, 1H), 9.32 (d, 2H, $J = 8.9$ Hz), 9.69 (d, 1H, $J =$

8.2 Hz); ^{13}C NMR (75 MHz, DMSO- d_6): δ 57.6, 61.7, 104.5, 109.7, 115.6, 120.5, 122.7, 124.6, 127.5, 127.9, 128.5, 128.7, 131.6, 131.9, 132.4, 134.6, 134.7, 136.5, 139.6, 144.5, 145.5, 146.3, 149.6, 153.4, 154.7, 159.6, 171.7; MS (ESI): m/z 619 $[\text{M} + \text{H}]^+$; Anal. Calcd for $\text{C}_{34}\text{H}_{26}\text{N}_4\text{O}_6\text{S}$: C, 66.01; H, 4.24; N, 9.06. Found: C, 66.17; H, 4.39; N, 9.22.

(2E)-3-(4-(3-(4-(3,4,5-Trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)-1-(3,5-dinitrophenyl)prop-2-en-1-one (12h)

This compound **12h** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 1-(3,5-dinitrophenyl)ethanone(**11h**) (210 mg, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 7:3) to afford pure compound **12h** as half white color solid, 410.3 mg with 58% yield. mp: 343–345 °C, ^1H NMR (300 MHz, DMSO- d_6): δ 3.87 (s, 6H), 3.90 (s, 3H), 7.16 (d, 1H, $J = 15.8$ Hz), 7.19–7.28 (m, 3H), 7.38 (s, 2H), 7.62 (t, 1H), 7.88–7.97 (m, 4H), 8.27 (s, 1H), 9.44 (s, 2H), 9.69 (d, 1H, $J = 8.2$ Hz), 9.73 (s, 1H); ^{13}C NMR (75 MHz, DMSO- d_6): δ 57.6, 61.7, 104.6, 109.8, 115.7, 120.5, 122.7, 125.6, 127.6, 127.9, 128.5, 128.7, 129.3, 131.6, 131.8, 134.6, 134.8, 136.8, 139.4, 145.6, 146.7, 149.6, 151.7, 154.8, 159.7, 171.8; MS (ESI): m/z 664 $[\text{M} + \text{H}]^+$; Anal. Calcd for $\text{C}_{34}\text{H}_{25}\text{N}_5\text{O}_8\text{S}$: C, 61.53; H, 3.80; N, 10.55. Found: C, 61.39; H, 3.93; N, 10.72.

4-((2E)-3-(4-(3-(4-(3,4,5-Trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)acryloyl) benzonitrile (12i)

This compound **12i** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 4-acetylbenzonitrile (**11i**) (145 mg, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 7:3) to afford pure compound **12i** as half white color solid, 106.8 mg with 17% yield. mp: 295–297 °C, ^1H NMR (300 MHz, DMSO- d_6): δ 3.87 (s, 6H), 3.90 (s, 3H), 7.14 (d, 1H, $J = 15.6$ Hz), 7.17–7.26 (m, 3H), 7.38 (s, 2H), 7.62 (t, 1H), 7.87–7.96 (m, 4H), 8.13 (d, 2H, $J = 8.8$ Hz), 8.27 (s, 1H), 9.51 (d, 2H, $J = 8.8$ Hz), 9.69 (d, 1H, $J = 8.2$ Hz); ^{13}C NMR (75 MHz, DMSO- d_6): δ 57.6, 16.7, 104.6, 109.8, 115.6, 116.4, 118.7, 120.5, 122.7, 127.6, 127.9, 128.5, 128.8, 131.5, 131.7, 132.4, 133.7, 134.7, 134.9, 136.5, 139.6, 142.5, 145.7, 146.4, 149.7, 154.6, 159.7, 171.8; MS (ESI): m/z 599 $[\text{M} + \text{H}]^+$; Anal. Calcd for $\text{C}_{35}\text{H}_{26}\text{N}_4\text{O}_4\text{S}$: C, 70.22; H, 4.38; N, 9.36. Found: C, 70.09; H, 5.00; N, 9.51.

(2E)-3-(4-(3-(4-(3,4,5-Trimethoxyphenyl)thiazol-2-yl)H-imidazo[1,2-a]pyridin-2-yl)phenyl)-1-p-tolylprop-2-en-1-one (12j)

This compound **12j** was prepared following the method described for the preparation of the compound **12a**, employing **10** (500 mg, 0.001 mmol) with 1-p-tolylethanone (**11j**) (0.13 ml, 0.001 mmol) and crude product was purified by column chromatography (ethyl acetate/hexane: 7:3) to afford pure compound **12j** as half white color solid, 241.7 mg with 39% yield. mp: 270–272 °C, ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.48 (s, 3H), 3.87 (s, 6H), 3.90 (s, 3H), 7.12 (d, 1H, *J* = 15.5 Hz), 7.18 (d, 2H, *J* = 8.6 Hz), 7.21 (t, 1H), 7.32–7.41 (m, 4H), 7.62 (t, 1H), 7.85–7.94 (m, 4H), 8.26 (s, 1H), 9.69 (d, 1H, *J* = 8.2 Hz); ¹³C NMR (75 MHz, DMSO-*d*₆): δ 24.8, 57.6, 61.7, 104.7, 109.7, 115.6, 120.7, 122.6, 127.5, 127.8, 128.5, 128.9, 129.5, 130.2, 131.6, 131.7, 1134.6, 134.8, 136.5, 136.8, 139.6, 144.5, 145.9, 146.4, 149.7, 154.6, 159.7, 170.6; MS (ESI): *m/z* 588 [M + H]⁺; Anal. Calcd for C₃₅H₂₉N₃O₄S: C, 71.53; H, 4.97; N, 7.15. Found: C, 71.66; H, 4.85; N, 7.03.

MTT assay

Individual wells of a 96-well tissue culture micro titer plate were inoculated with 100 μL of complete medium containing 1 × 10⁴ cells. The plates were incubated at 37 °C in a humidified 5% CO₂ incubator for 18 h prior to the experiment. After medium removal, 100 μL of fresh medium containing the test compounds and etoposide (Eto) at different concentrations such as 0.5, 1, and 2 μM were added to each well and incubated at 37 °C for 24 h. Then the medium was discarded and replaced with 10 μL MTT dye. Plates were incubated at 37 °C for 2 h. The resulting formazan crystals were solubilized in 100 μL extraction buffer. The optical density (OD) was read at 570 nm with the micro plate reader (Multi-mode Varioskan Instrument-Thermo Scientific). The percentage of DMSO in the medium never exceeded 0.25%.

Molecular docking studies

The X-ray crystal structure protein kinase CLK1 (PDB: 5X8I), with resolution 1.91 Å; *R*-value: 0.168 (obs.) was obtained from the protein data bank www.rcsb.org/structure/5X8I. The ligands were saved as mol file. The molecular docking studies were performed as per the reported protocol (Sun et al. 2017; ElHady et al. 2017).

Conclusion

In conclusion, A new library of chalcone linked thiazole-imidazopyridine (**12a–j**) were synthesized and screened

their anticancer effects on four human cancer cell lines including MCF-7 (breast carcinoma), A549 (lung carcinoma), DU-145 (prostate carcinoma), and MDA MB-231 (breast carcinoma) by employing MTT method and etoposide used as positive control. Among them, compound **12b** exhibited potent anticancer activities against four cancer cell lines than positive control. This compound may act as drug lead one in cancer chemotherapy.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Agarwal M, Singh V, Sharma SC, Sharma P, Ansari MdY, Jadav SS, Yasmin S, Sreenivasulu R, Hassan MdH (2016) Design and synthesis of new 2,5-disubstituted 1,3,4-oxadiazole analogues as anticancer agents. *Med Chem Res* 25:2289–2303
- Ahsan MJ, Choudhary K, Jadav SS, Yasmin S, Ansari MY, Sreenivasulu R (2015) Synthesis, antiproliferative activity and molecular docking studies of curcumin analogues bearing pyrazole ring. *Med Chem Res* 24:4166–4180
- Al-Tel TH, Al-Qawasmeh RA, Zaarour R (2011) Design, synthesis and in vitro antimicrobial evaluation of novel imidazo[1,2-a]pyridine and imidazo[2,1-b][1,3]benzothiazole motifs. *Eur J Med Chem* 46:1874–1881
- Bukowski L, Kaliszan R (1991) Imidazo[4,5-b]pyridine derivatives of potential tuberculostatic activity. II: synthesis and bioactivity of designed and some other 2-cyanomethylimidazo[4,5-b]pyridine derivatives. *Arch Pharm* 9:537–542
- Byth KF, Geh C, Förder CL, Oakes SE, Thomas AP (2006) The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor. *Mol Cancer Ther* 5:655–664
- Cheenpracha S, Karalai C, Ponglimanont C, Subhadhirasakul S, Tewtrakul S (2006) Anti-HIV-1 protease activity of compounds from *Boesenbergia pandurata*. *Bioorg Med Chem* 14:1710–1714
- Clayton PE, Banerjee I, Murray PG, Renehan AG (2011) Growth hormone, the insulin-like-growth factor axis, insulin and cancer risk. *Nat Rev Endocrinol* 7:11–24
- Clemens MR (1991) Free radicals in chemical carcinogenesis. *Klin-Wochenschr* 69:1123–1134
- Dimmock JR, Kandepu NM, Hetherington M, Quail JW, Pugazhenthii U, Sudom AM, Chamankhah M, Rose P, Pass E, Allen TM, Halleran S, Szydowski J, Mutus B, Tannous M, Manavathu EK, Myers TG, Clercq ED, Balzarini J (1998) Cytotoxic activities of mannich bases of chalcones and related compounds. *J Med Chem* 41:1014–1026
- Ducki S, Forrest R, Hadfield JA, Kendall A, Lawrence NJ, McGrown AT, Rennison D (1998) Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure–activity relationship analysis. *Bioorg Med Chem Lett* 8:1051–1056
- Durgesh R, Sreenivasulu R, Srinivasarao P, Raju RR (2018a) Synthesis and anti-tumor evaluation of novel 5-bromo indole-aryl ketohydrazide-hydrazone analogues. *Asian J Chem* 30:1201–1204

- Durgesh R, Sreenivasulu R, Srinivasarao P, Raju RR (2018b) Synthesis and anticancer evaluation of indazole-aryl hydrazide-hydrazone derivatives. *J Ind Chem Soc* 95:433–438
- Durgesh R, Sreenivasulu R, Raju RR (2018c) Synthesis and anti-tumor evaluation of Indole-substituted Indole fused keto hydrazide-hydrazones. *J Pharm Res* 12:42–46
- ElHady AK, Abdel-Halim, Abadi MAH, Engel M (2017) Development of selective Cdk1 and -4 inhibitors for cellular depletion of cancer-relevant proteins. *J Med Chem* 60:5377–5391
- Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MYWT, Darzynkiewicz Z, Wu JM (2004) Licochalcone-A, a novel flavonoid isolated from licorice root (*Glycyrrhiza glabra*), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. *Biochem Biophys Res Commun* 322:263–270
- Furman C, Lebeau J, Fruchart JC, Bernier JL, Duez P, Cotelte N, Teissier E (2001) Di-tert-butylhydroxylated flavonoids protect endothelial cells against oxidized LDL-induced cytotoxicity. *J Biochem Mol Toxicol* 15:270–278
- Go ML, Wu X, Liu XL (2005) Chalcones: an update on cytotoxic and chemo protective properties. *Curr Med Chem* 12:481–499
- Gudmundsson KS, Williams JD, Drach JC, Townsend LB (2003) Synthesis and antiviral activity of novel erythrofuransyl imidazo [1,2-a]pyridine C-nucleosides constructed via palladium coupling of iodoimidazo[1,2-a]pyridines and dihydrofuran. *J Med Chem* 46:1449–1455
- Gueiffier A, Mavel S, Lhassani M, Elhakmaoui A, Snoeck R, Andrei G, Chavignon O, Teulade JC, Witvrouw M, Balzarini J, De Clercq E, Chapat JP (1998) Synthesis of imidazo[1,2-a]pyridines as antiviral agents. *J Med Chem* 41:5108–5112
- Harrison TS, Keating GM (2005) Zolpidem: a review of its use in the management of insomnia. *CNS Drugs* 19:65–89
- Hatti I, Sreenivasulu R, Jadav SS, Ahsan MJ, Raju RR (2015a) Synthesis and biological evaluation of 1,3,4-oxadiazole linked bis indole derivatives as anticancer agents. *Monatsh Chem* 146:1699–1705
- Hatti I, Sreenivasulu R, Jadav SS, Jayaprakash V, Kumar CG, Raju RR (2015b) Synthesis, cytotoxic activity and docking studies of new 4 - aza podophyllotoxin derivatives. *Med Chem Res* 24:3305–3313. <https://www.rcsb.org/5X8I>
- John R, Ross H (2010) The global economic cost of cancer. American Cancer Society, Atlanta
- Kamal A, Kumar GB, Nayak VL, Reddy VS, Shaik AB, Rajender K, Reddy MK (2015) Design, synthesis and biological evaluation of imidazopyridine/imidazopyrimidine-benzimidazole conjugates as potential anticancer agents. *Med Chem Commun* 6:606–612
- Kamal A, Reddy JS, Ramaiah MJ, Dastagiri D, Bharathi EV, Sagar MVP, Pushpavalli SNCVL, Ray P, Pal-Bhadra M (2010) Design, synthesis and biological evaluation of imidazopyridine/pyrimidine-chalcone derivatives as potential anticancer agents. *Med Chem Commun* 1:355–360
- Kercher T, Rao C, Bencsik JR, Josey JA (2007) Diversification of the three-component coupling of 2-aminoheterocycles, aldehydes, and isonitriles: efficient parallel synthesis of a diverse and drug-like library of imidazo- and tetrahydroimidazo[1,2-a]heterocycles. *J Comb Chem* 9:1177–1187
- Lacerda RB, de Lima CK, da Silva LL, Romeiro NC, Miranda AL, Barreiro EJ, Fraga CA (2009) Discovery of novel analgesic and anti-inflammatory 3-arylamino-imidazo[1,2a]pyridine symbiotic prototypes. *Bioorg Med Chem* 17:74–84
- Lahtchev KL, Batovska DI, Parushev SP, Ubiyovok VM, Sibirny AA (2008) Antifungal activity of chalcones: a mechanistic study using various yeast strains. *Eur J Med Chem* 43:2220–2228
- Lancel M, Steiger A (1999) Sleep and its modulation by drugs that affect GABA_A receptor function. *Angew Chem Int Ed* 38:2852–2864
- Langer SZ, Arbilla S, Benavides J, Scotton B (1990) Zolpidem and alpidem: two imidazopyridines with selectivity for omega 1- and omega 3-receptor subtypes. *Adv Biochem Psychopharmacol* 46:61–72
- Larsen M, Kromann H, Kharazmi A, Nielsen SF (2005) Conformationally restricted anti plasmodial chalcones. *Bioorg Med Chem Lett* 15:4858–4861
- Liaras K, Geronikaki A, Glamoclija J, Ciric A, Sokovic M (2011) Thiazole-based chalcones as potent antimicrobial agents. Synthesis and biological evaluation. *Bioorg Med Chem Lett* 19:3135–3140
- Lin YM, Zhou LM, Flavin MT, Nie W, Chen FC (2002) Chalcones and flavonoids as anti-tuberculosis agents. *Bioorg Med Chem* 10:2795–2802
- Madhavi S, Sreenivasulu R, Ansari MdY, Ahsan MJ, Raju RR (2016) Synthesis, biological evaluation and molecular docking studies of pyridine incorporated chalcone derivatives as anticancer agents. *Lett Org Chem* 13:682–692
- Madhavi S, Sreenivasulu R, Jyotsna Y, Raju RR (2017a) Synthesis of chalcone incorporated quinazoline derivatives as anticancer agents. *Saudi Pharm J* 25:275–279
- Madhavi S, Sreenivasulu R, Raju RR (2017b) Synthesis and biological evaluation of oxadiazole incorporated ellipticine derivatives as anticancer agents. *Monatsh Chem* 148:933–938
- Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. *Nature* 454:436–444
- Meffert MK, Chang JM, Wiltgen BJ, Fanselow MS, Baltimore D (2003) NF-kappa B functions in synaptic signaling and behaviour. *Nat Neurosci* 6:1072–1078
- Modzelewska A, Pettit C, Achanta G, Davidson NE, Huang P, Khan SR (2006) Anticancer activities of novel chalcone and bis-chalcone derivatives. *Bioorg Med Chem* 14:3491–3495
- Murthy IS, Sreenivasulu R, Alluraiah G, Raju RR (2019) Design, synthesis and anticancer evaluation of 1,2,3-triazole linked 1,2-isoxazole - imidazo[4,5-b]pyridine derivatives. *Russian J Gen Chem* 89:1718–1723
- Nielsen SF, Christensen SB, Cruciani G, Kharazmi A, Liljefors T (1998) Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure–activity relationship analysis. *J Med Chem* 41:4819–4832
- Nowakowska Z (2007) A review of anti-infective and anti-inflammatory chalcones. *Eur J Med Chem* 42:125–137
- Park SK, Cho LY, Yang JJ, Park B, Chang SH, Lee KS, Kim H, Yoo KY, Lee CT (2010) Lung cancer risk and cigarette smoking, lung tuberculosis according to histologic type and gender in a population based case-control study. *Lung Cancer* 68:20–26
- Porta C, Riboldi E, Sica A (2011) Mechanisms linking pathogen-associated inflammation and cancer. *Cancer Lett* 305:250–262
- Pragathi YJ, Sreenivasulu R, Veronica D, Madhavi S, Raju RR (2019) Design, synthesis and biological evaluation of novel 2-(4-aryl-substituted-1H-1,2,3-triazol-1-yl)-N-(4-(2-(thiazol-2-yl)benzo[d]thiazol-6-yl)phenyl) acetamide derivatives as potent anticancer agents. *Russian J Gen Chem* 89:1009–1014
- Rao BVD, Sreenivasulu R, Rao MVB (2019) Design, synthesis, and evaluation of isoxazole-thiadiazole linked carbazole hybrids as anticancer agents. *Russian J Gen Chem* 89:2115–2120
- Reddy NB, Burra VR, Ravindranath LK, Kumar VN, Sreenivasulu R, Sadanandam P (2016a) Synthesis and biological evaluation of benzimidazole fused ellipticine derivatives as anticancer agents. *Monatsh Chem* 147:599–604
- Reddy NB, Burra VR, Ravindranath LK, Sreenivasulu R, Kumar VN (2016b) Synthesis and biological evaluation of benzoxazole fused combretastatin derivatives as anticancer agents. *Monatsh Chem* 147:593–598
- Reddy KT, Sreenivasulu R, Raju RR (2019) Synthesis and biological evaluation of 1,2,4-oxadiazole linked imidazopyrazine derivatives as anticancer agents. *J Ind Chem Soc* 96:1085–1090

- Rival Y, Grassy G, Taudon A, Ecalle R (1991) Antifungal activity in vitro of some imidazo[1,2-a]pyrimidine derivatives. *Activité antifongique in vitro de quelques dérivés de l'imidazo[1,2-a]pyrimidine*. *Eur J Med Chem* 26:13–18
- Rojas J, Payá M, Domínguez JN, Ferrándiz ML (2003) ttCH, a selective inhibitor of inducible nitric oxide synthase expression with antiarthritic properties. *Eur J Pharmacol* 465:183–189
- Rozmer Z, Perjési P (2016) Naturally occurring chalcones and their biological activities. *Phytochem Rev* 15:87–120
- Satyanarayana M, Tiwari P, Tripathi BK, Srivastava AK, Pratap R (2004) Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines. *Bioorg Med Chem* 12:883–889
- Shahinshavali S, Sreenivasulu R, Guttikonda VR, Kolli D, Rao MVB (2019) Synthesis and anticancer activity of amide derivatives of 1,2-isoxazole combined 1,2,4-thiadiazole. *Russian J Gen Chem* 89:324–329
- Spandana Z, Sreenivasulu R, Rao MVB (2018a) Design, synthesis and anticancer evaluation of carbazole fused aminopyrimidine derivatives. *Lett Org Chem* 16:662–667
- Spandana Z, Sreenivasulu R, Rekha TM, Rao MVB (2018b) Novel 1,3,4-oxadiazole fused thiadiazole derivatives: synthesis and study of anticancer activities. *Lett Drug Des Discov* 16:656–662
- Sreenivasulu R, Durgesh R, Jadav SS, Sujitha P, Kumar CG, Raju RR (2018) Synthesis, anticancer evaluation and molecular docking studies of Bis(indolyl)triazinones, Nortopsentin analogues. *Chem Pap* 72:1369–1378
- Sreenivasulu R, Sujitha P, Jadav SS, Ahsan MJ, Kumar CG, Raju RR (2017) Synthesis, antitumor evaluation and molecular docking studies of Indole-Indazolyl hydrazide hydrazone derivatives. *Monatsh Chem* 148:305–314
- Sreenivasulu R, Reddy KT, Jadav SS, Sujitha P, Kumar CG, Raju RR (2019) Synthesis, antiproliferative and apoptosis induction potential activities of novel bis(indolyl) hydrazide-hydrazone derivatives. *Bioorg Med Chem* 27:1043–1055
- Sreenivasulu R, Tej MB, Jadav SS, Sujitha P, Kumar CG, Raju RR (2020) Synthesis, anticancer evaluation and molecular docking studies of 2,5-bis(indolyl)-1,3,4-oxadiazoles, Nortopsentin analogues. *J Mol Struct* 1208:127875
- Starrett JE, Montzka TA, Crosswell AR, Cavanagh RL (1989) Synthesis and biological activity of 3-substituted imidazo[1,2-a]pyridines as antiulcer agents. *J Med Chem* 32:2204–2210
- Subramanyam M, Sreenivasulu R, Rambabu G, Rao MVB, Rao KP (2018) Synthesis, biological evaluation and docking studies of 1,3,4-oxadiazole fused benzothiazole derivatives for anticancer drugs. *Lett Drug Des Discov* 15:1299–1307
- Suma VR, Sreenivasulu R, Subramanyam M, Rao KRM (2019) Design, synthesis and anticancer activity of amide derivatives of structurally modified combretastatin-A₄. *Russian J Gen Chem* 89:499–504
- Sun QZ, Lin GF, Li LL, Jin XT, Huang LY, Zhang G, Yang W, Chen X, Xiang R, Chen C, Wei YQ, Lu GW, Yang SY (2017) Discovery of potent and selective inhibitors of Cdc2-like kinase 1 (CLK1) as a new class of autophagy inducers. *J Med Chem* 60:6337–6352
- Temple C (1990) Antimitotic agents. Synthesis of imidazo[4,5-c]pyridine-6-ylcarbamates and imidazo[4,5-b]pyridine-5-ylcarbamates. *J Med Chem* 33:656–661
- Choi HG, Son JB, Kim S, Lee S, Ko E, Cho J, Kang SY, Kim SY, Park JH, Ko YK, Ryu HY, Kim ND, Kim H, Lee Y, Lee SH, Kim D, Lee SJ, Hong S, Min SH, Lee S, Choi DK, Bae JH, Hong E, Jang T, Song J, Kim S, Yoon SK (2017) Novel imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer. *WO2017222285A1*
- Yakantham T, Sreenivasulu R, Raju RR (2019) Design, synthesis and anticancer evaluation of 2-(3-(4-((5-aryl-1,2,4-oxadiazol-3-yl)methoxy)phenyl)isoxazol-5-yl)-N-(3,4,5-trimethyl phenyl)thiazol-4-amine derivatives. *Russ J Gen Chem* 89:1485–1490
- Yoon G, Kang BY, Cheon SH (2007) Topoisomerase I inhibition and cytotoxicity of licochalcones A and E from *Glycyrrhiza inflata*. *Arch Pharm Res* 30:313–316